Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Clinical trial NCT07252232 · RECRUITING

Trial details

NCT number: NCT07252232
Sponsor: Revolution Medicines, Inc.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Pancreatic Cancer PDAC PDAC - Pancreatic Ductal Adenocarcinoma Resectable Pancreatic Ductal Adenocarcinoma (PDAC)Resected Pancreatic Adenocarcinoma

Start date: 2025-12-15
Primary completion: 2029-05-10
Enrollment: 500

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.